Free Trial
NASDAQ:SABS

SAB Biotherapeutics Q4 2024 Earnings Report

SAB Biotherapeutics logo
$1.60 -0.10 (-5.88%)
Closing price 05/2/2025 03:58 PM Eastern
Extended Trading
$1.60 0.00 (0.00%)
As of 05/2/2025 04:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

SAB Biotherapeutics EPS Results

Actual EPS
-$1.23
Consensus EPS
-$1.16
Beat/Miss
Missed by -$0.07
One Year Ago EPS
N/A

SAB Biotherapeutics Revenue Results

Actual Revenue
$0.05 million
Expected Revenue
$0.12 million
Beat/Miss
Missed by -$70.00 thousand
YoY Revenue Growth
N/A

SAB Biotherapeutics Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
Sunday, March 30, 2025
Conference Call Time
6:00PM ET

Upcoming Earnings

SAB Biotherapeutics' Q1 2025 earnings is scheduled for Monday, May 19, 2025, with a conference call scheduled at 7:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

SAB Biotherapeutics Earnings Headlines

Reviewing SAB Biotherapeutics (SABS) and Its Rivals
SAB Biotherapeutics (SABS) versus Its Peers Head-To-Head Review
Donald Trump is about to free crypto from its chains …
Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election … surpassing $100,000 on Dec. 8 .… Now Juan believes it could hit $150,000 … or higher in 2025.
Analyzing SAB Biotherapeutics (SABS) & Its Peers
See More SAB Biotherapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like SAB Biotherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on SAB Biotherapeutics and other key companies, straight to your email.

About SAB Biotherapeutics

SAB Biotherapeutics (NASDAQ:SABS), a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases. The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma. In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte globulin treatment, currently under Phase 1 trials in delaying the onset or progression of type 1 diabetes. Further, the company develops SAB-176, a multivalent, broadly neutralizing - human polyclonal immunoglobulin therapeutic candidate, currently in Phase 2a development for the treatment or prevention of severe influenza. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Miami Beach, Florida.

View SAB Biotherapeutics Profile

More Earnings Resources from MarketBeat